This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Suzuki, H. Articles by Nagai, A. Search for Related Content PubMed PubMed Citation Articles by Suzuki, H. Articles by Nagai, A.

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibition Augments a Murine Model of Pulmonary Fibrosis¹

First Department of Medicine, Tokyo Women’s Medical University, Tokyo 162-8666, Japan

The inappropriate regeneration of sequentially injured epithelium is an important process leading to pulmonary fibrosis. Previous studies have shown that the epithelial expression of epidermal growth factor receptor (EGFR) is increased in fibrotic lung tissue, compared with normal lung tissue, suggesting that EGFR-mediated signaling is involved in epithelial regeneration in fibrotic lung diseases. We examined the effect of EGFR inhibition using ZD1839, a selective EGFR tyrosine kinase inhibitor (TKI), on bleomycin-induced pulmonary fibrosis in mice. ICR mice were administered a single intratracheal injection of bleomycin (5 units/kg) on day 1. ZD1839 (200 mg/kg) or vehicle alone were administered p.o. 1 h before this injection and on days 1–5 each week for 3 weeks. Lung tissue was harvested on day 21. Lung histology and collagen analysis performed on day 21 showed more severe fibrosis in the mice receiving both bleomycin and the EGFR-TKI than in the mice receiving bleomycin and the vehicle. An immunohistochemistry analysis showed that phosphorylated EGFR and proliferation cell nuclear antigen were highly expressed by the regenerated epithelial cells in the mice treated with bleomycin and the vehicle. In contrast, the expression of these antigens was attenuated in the mice treated with bleomycin and the EGFR-TKI. In vitro studies also demonstrated that the addition of ZD1839 at a concentration of 1 µM suppressed the proliferation of type II-like epithelial cells (A549) but not that of lung fibroblasts (IMR90). These results suggest that the inhibition of EGFR phosphorylation augments bleomycin-induced pulmonary fibrosis by reducing regenerative epithelial proliferation. Our data suggest that EGFR-TKIs should be used with caution in cancer patients with pulmonary fibrosis.

This article has been cited by other articles:

				S. Kudoh, H. Kato, Y. Nishiwaki, M. Fukuoka, K. Nakata, Y. Ichinose, M. Tsuboi, S. Yokota, K. Nakagawa, M. Suga, et al. Interstitial Lung Disease in Japanese Patients with Lung Cancer: A Cohort and Nested Case-Control Study Am. J. Respir. Crit. Care Med., June 15, 2008; 177(12): 1348 - 1357. [Abstract] [Full Text] [PDF]

				W. D. Hardie, C. Davidson, M. Ikegami, G. D. Leikauf, T. D. Le Cras, A. Prestridge, J. A. Whitsett, and T. R. Korfhagen EGF receptor tyrosine kinase inhibitors diminish transforming growth factor-{alpha}-induced pulmonary fibrosis Am J Physiol Lung Cell Mol Physiol, June 1, 2008; 294(6): L1217 - L1225. [Abstract] [Full Text] [PDF]

				J. A. Faress, D. E. Nethery, E. F. O. Kern, R. Eisenberg, F. J. Jacono, C. L. Allen, and J. A. Kern Bleomycin-induced pulmonary fibrosis is attenuated by a monoclonal antibody targeting HER2 J Appl Physiol, December 1, 2007; 103(6): 2077 - 2083. [Abstract] [Full Text] [PDF]

				V. Liu, D. A. White, M. F. Zakowski, W. Travis, M. G. Kris, M. S. Ginsberg, V. A. Miller, and C. G. Azzoli Pulmonary Toxicity Associated With Erlotinib Chest, September 1, 2007; 132(3): 1042 - 1044. [Abstract] [Full Text] [PDF]

				Y. Ishii, S. Fujimoto, and T. Fukuda Gefitinib Prevents Bleomycin-induced Lung Fibrosis in Mice Am. J. Respir. Crit. Care Med., September 1, 2006; 174(5): 550 - 556. [Abstract] [Full Text] [PDF]

				M. Ando, I. Okamoto, N. Yamamoto, K. Takeda, K. Tamura, T. Seto, Y. Ariyoshi, and M. Fukuoka Predictive Factors for Interstitial Lung Disease, Antitumor Response, and Survival in Non-Small-Cell Lung Cancer Patients Treated With Gefitinib J. Clin. Oncol., June 1, 2006; 24(16): 2549 - 2556. [Abstract] [Full Text] [PDF]

				D. E. Nethery, B. B. Moore, G. Minowada, J. Carroll, J. A. Faress, and J. A. Kern Expression of mutant human epidermal receptor 3 attenuates lung fibrosis and improves survival in mice J Appl Physiol, July 1, 2005; 99(1): 298 - 307. [Abstract] [Full Text] [PDF]

				R. Vittal, J. C. Horowitz, B. B. Moore, H. Zhang, F. J. Martinez, G. B. Toews, T. J. Standiford, and V. J. Thannickal Modulation of Prosurvival Signaling in Fibroblasts by a Protein Kinase Inhibitor Protects against Fibrotic Tissue Injury Am. J. Pathol., February 1, 2005; 166(2): 367 - 375. [Abstract] [Full Text] [PDF]

				B. Bostrom, J. Sidman, S. Marker, T. Lander, and D. Drehner Gefitinib Therapy for Life-Threatening Laryngeal Papillomatosis Arch Otolaryngol Head Neck Surg, January 1, 2005; 131(1): 64 - 67. [Full Text] [PDF]

				J. A. Whitsett, C. J. Bachurski, K. C. Barnes, P. A. Bunn Jr., L. M. Case, D. N. Cook, D. Crooks, M. W. Duncan, L. Dwyer-Nield, R. C. Elston, et al. Functional Genomics of Lung Disease Am. J. Respir. Cell Mol. Biol., August 1, 2004; 31(2/S1): S1 - S81. [Full Text] [PDF]